seratrodast has been researched along with (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, K; Niwa, S; Sakakibara, A; Takagi, K; Wakayama, H; Yagi, T | 1 |
1 trial(s) available for seratrodast and (9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
| Article | Year |
|---|---|
Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein.
Topics: Adult; Aged; Analysis of Variance; Asthma; Beclomethasone; Benzoquinones; Blood Proteins; Chromones; Chronic Disease; Drug Therapy, Combination; Eosinophil Granule Proteins; Female; Glucocorticoids; Heptanoic Acids; Humans; Leukotriene Antagonists; Male; Middle Aged; Prognosis; Prospective Studies; Prostaglandin Antagonists; Respiratory Mechanics; Ribonucleases; Statistics, Nonparametric | 2002 |